ATE95060T1 - Verwendung von c-22 bis c-26-aliphatischen alkoholen zur behandlung entzuendlicher und viraler hauterkrankungen. - Google Patents

Verwendung von c-22 bis c-26-aliphatischen alkoholen zur behandlung entzuendlicher und viraler hauterkrankungen.

Info

Publication number
ATE95060T1
ATE95060T1 AT90906552T AT90906552T ATE95060T1 AT E95060 T1 ATE95060 T1 AT E95060T1 AT 90906552 T AT90906552 T AT 90906552T AT 90906552 T AT90906552 T AT 90906552T AT E95060 T1 ATE95060 T1 AT E95060T1
Authority
AT
Austria
Prior art keywords
aliphatic alcohols
inflammatory
treatment
skin diseases
viral skin
Prior art date
Application number
AT90906552T
Other languages
English (en)
Inventor
David H Katz
Original Assignee
Lidak Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lidak Pharmaceuticals filed Critical Lidak Pharmaceuticals
Application granted granted Critical
Publication of ATE95060T1 publication Critical patent/ATE95060T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT90906552T 1989-04-28 1990-04-16 Verwendung von c-22 bis c-26-aliphatischen alkoholen zur behandlung entzuendlicher und viraler hauterkrankungen. ATE95060T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/345,084 US4874794A (en) 1989-04-28 1989-04-28 Inflammatory disease treatment
PCT/US1990/002045 WO1990013216A2 (en) 1989-04-28 1990-04-16 Inflammatory disease treatment

Publications (1)

Publication Number Publication Date
ATE95060T1 true ATE95060T1 (de) 1993-10-15

Family

ID=23353439

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90906552T ATE95060T1 (de) 1989-04-28 1990-04-16 Verwendung von c-22 bis c-26-aliphatischen alkoholen zur behandlung entzuendlicher und viraler hauterkrankungen.

Country Status (10)

Country Link
US (1) US4874794A (de)
EP (1) EP0428642B1 (de)
JP (1) JPH03505882A (de)
AT (1) ATE95060T1 (de)
DE (2) DE69003652T2 (de)
DK (1) DK0428642T3 (de)
ES (1) ES2060158T3 (de)
HK (1) HK120497A (de)
NL (1) NL300354I2 (de)
WO (1) WO1990013216A2 (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5370871A (en) * 1983-01-24 1994-12-06 The Johns Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US5380754A (en) * 1988-02-29 1995-01-10 Virotex Corporation Topical composition enhancing healing of viral lesions
US5135956A (en) * 1988-10-18 1992-08-04 The Regents Of The University Of California Method of using cytoprotective alcohols to treat neural disease and neural injury
CA2044162A1 (fr) * 1989-10-13 1991-04-14 Jacques Borg Derives des alcools gras a longue chaine, leurs applications, notamment en tant que molecules cytotrophes et cytoprotectrices, et compositions pharmaceutiques les contenant
US5296514A (en) * 1991-04-23 1994-03-22 Summit Technology, Inc. Corneal treatment agents
US5098896A (en) * 1991-04-23 1992-03-24 Summit Technology, Inc. Corneal treatment agents
US5214071A (en) * 1991-04-23 1993-05-25 Summit Technology, Inc. Corneal treatment agents
US5198217A (en) * 1991-09-24 1993-03-30 Choice Pharmaceuticals Topical demulcent for viral and inflammatory diseases of the skin
CN1103586C (zh) * 1993-12-13 2003-03-26 里达克药品公司 蔗糖酯－c20－28醇制剂
US5952392A (en) * 1996-09-17 1999-09-14 Avanir Pharmaceuticals Long-chain alcohols, alkanes, fatty acids and amides in the treatment of burns and viral inhibition
US6440980B1 (en) * 1996-09-17 2002-08-27 Avanir Pharmaceuticals Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
US5948822A (en) 1996-12-17 1999-09-07 Lidak Pharmaceuticals Treatment of hyperproliferative skin disorders with C18 to C26 alphatic alcohols
US20050203187A1 (en) * 1998-06-01 2005-09-15 Verbiscar Anthony J. Formulations useful for the treatment of varicella zoster virus infections and methods for the use thereof
ES2242582T3 (es) 1999-09-03 2005-11-16 Cabby Business Inc. Procedimiento de alta eficiencia para la preparacion de esteroles de alta pureza.
US8173709B2 (en) * 1999-09-22 2012-05-08 Quadex Pharmaceuticals, Llc Anti-infective methods for treating pathogen-induced disordered tissues
PT102410A (pt) * 2000-02-03 2001-08-30 Qualitas Lab Extraccao da fraccao ceroide do residuo resinoso de fabricacao de aglomerado negro de cortica com fluido supercritico
ATE336267T1 (de) * 2000-04-12 2006-09-15 Liplasome Pharma As Auf lipiden basierendes system zur zielgerichteten verabreichung diagnostischer wirkstoffe
US8512718B2 (en) 2000-07-03 2013-08-20 Foamix Ltd. Pharmaceutical composition for topical application
HRP20040421B1 (hr) * 2001-10-16 2013-05-31 Avanir Pharmaceuticals INHIBICIJA VIRUSA n-DOKOZANOLOM
DE10203688A1 (de) 2002-01-31 2003-08-07 Bayer Cropscience Ag Synergistische insektizide Mischungen
DE10207242A1 (de) * 2002-02-21 2003-09-04 Bayer Cropscience Ag Synergistische insektizide Mischungen
US7214394B2 (en) * 2002-05-31 2007-05-08 Archer-Daniels-Midland Company Policosanol compositions, extraction from novel sources, and uses thereof
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US20080138296A1 (en) 2002-10-25 2008-06-12 Foamix Ltd. Foam prepared from nanoemulsions and uses
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US8486376B2 (en) 2002-10-25 2013-07-16 Foamix Ltd. Moisturizing foam containing lanolin
US7700076B2 (en) * 2002-10-25 2010-04-20 Foamix, Ltd. Penetrating pharmaceutical foam
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US9668972B2 (en) 2002-10-25 2017-06-06 Foamix Pharmaceuticals Ltd. Nonsteroidal immunomodulating kit and composition and uses thereof
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US8119150B2 (en) * 2002-10-25 2012-02-21 Foamix Ltd. Non-flammable insecticide composition and uses thereof
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US8119109B2 (en) 2002-10-25 2012-02-21 Foamix Ltd. Foamable compositions, kits and methods for hyperhidrosis
AU2003279493B2 (en) 2002-10-25 2009-08-20 Foamix Pharmaceuticals Ltd. Cosmetic and pharmaceutical foam
US8900554B2 (en) 2002-10-25 2014-12-02 Foamix Pharmaceuticals Ltd. Foamable composition and uses thereof
US7575739B2 (en) 2003-04-28 2009-08-18 Foamix Ltd. Foamable iodine composition
US8486374B2 (en) 2003-08-04 2013-07-16 Foamix Ltd. Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses
US8795693B2 (en) 2003-08-04 2014-08-05 Foamix Ltd. Compositions with modulating agents
CA2776692C (en) 2003-08-25 2014-12-30 Foamix Ltd. Penetrating pharmaceutical foam
US20050074443A1 (en) * 2003-10-03 2005-04-07 Treadwell Benjamin V. Methods of attenuating autoimmune disease and compositions useful therefor
CA2609953A1 (en) 2005-05-09 2007-04-12 Foamix Ltd. Saccharide foamable compositions
US20080260655A1 (en) 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
WO2009069006A2 (en) 2007-11-30 2009-06-04 Foamix Ltd. Foam containing benzoyl peroxide
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
WO2010041141A2 (en) 2008-10-07 2010-04-15 Foamix Ltd. Oil-based foamable carriers and formulations
AU2009205314A1 (en) 2008-01-14 2009-07-23 Foamix Ltd. Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses
US20120087872A1 (en) 2009-04-28 2012-04-12 Foamix Ltd. Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof
WO2011013009A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011013008A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011064631A1 (en) 2009-10-02 2011-06-03 Foamix Ltd. Surfactant-free, water-free, foamable compositions and breakable foams and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US8470833B2 (en) 2009-12-15 2013-06-25 Mcneil-Ppc, Inc. Hair growth and/or regrowth compositions
US8470880B2 (en) 2009-12-15 2013-06-25 Mcneil-Ppc, Inc. Methods of reducing hair loss and/or facilitating hair growth and/or regrowth
WO2011112997A1 (en) 2010-03-11 2011-09-15 Chemic Laboratories, Inc. Novel compositions and methods
US8846725B2 (en) 2011-01-24 2014-09-30 Quadex Pharmaceuticals, Llc Highly penetrating compositions and methods for treating pathogen-induced disordered tissues
US9549930B2 (en) 2013-03-14 2017-01-24 Quadex Pharmaceuticals, Llc Combined systemic and topical treatment of disordered and/or prodromal stage tissue
US9125911B2 (en) 2013-03-14 2015-09-08 Quadex Pharmaceuticals, Llc Combined systemic and topical treatment of disordered tissues
US9463180B2 (en) 2013-03-14 2016-10-11 Quadex Pharmaceuticals, Llc Treatment of molluscum contagiosum
US9675537B2 (en) 2014-06-30 2017-06-13 Johnson & Johnson Consumer Inc. Hair growth composition and method
CA2995794A1 (en) 2015-08-20 2017-02-23 Mitchell Shirvan Tetracycline management of egfr inhibitor associated dermatoses
US10561593B2 (en) 2015-12-28 2020-02-18 Johnson & Johnson Consumer Inc. Hair growth composition and method
MX377365B (es) 2016-09-08 2025-03-10 Journey Medical Corp Composiciones y métodos para tratar rosácea y acné.
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
EP4003302A1 (de) 2019-07-31 2022-06-01 Journey Medical Corporation Zusammensetzungen und verfahren und verwendungen davon
EP4084776A1 (de) 2019-12-31 2022-11-09 Vyne Therapeutics Inc. Topische zusammensetzung mit tofacitinib und fingolimod

Also Published As

Publication number Publication date
NL300354I1 (nl) 2008-08-01
DK0428642T3 (da) 1994-02-21
DE69003652T2 (de) 1994-03-24
DE69003652D1 (de) 1993-11-04
EP0428642B1 (de) 1993-09-29
WO1990013216A2 (en) 1990-11-15
HK120497A (en) 1997-09-05
NL300354I2 (nl) 2008-10-01
DE122007000080I2 (de) 2008-11-06
ES2060158T3 (es) 1994-11-16
EP0428642A1 (de) 1991-05-29
JPH03505882A (ja) 1991-12-19
DE122007000080I1 (de) 2008-02-28
US4874794A (en) 1989-10-17

Similar Documents

Publication Publication Date Title
ATE95060T1 (de) Verwendung von c-22 bis c-26-aliphatischen alkoholen zur behandlung entzuendlicher und viraler hauterkrankungen.
ATE227587T1 (de) Kombinierte verwendung von hyaluronsäure und therapeutischen wirkstoffen zur verbesserung des therapeutischen effekts
DE3752045D1 (de) Verwendung von Hydroxycarbonsäuren und Derivaten zur Herstellung topischer dermatologischer Zubereitungen zur Behandlung von Falten
DE3588023D1 (de) Mittel zur Behandlung von Herzerkrankungen.
DE3684190D1 (de) Verwendung von tetrahydrobiopterinen zur herstellung eines medikaments zur behandlung von kinderautismus.
ATE202701T1 (de) Behandlung und prophylaxe von durch parasiten oder bakterien verursachten erkrankungen
ATE56366T1 (de) Verband fuer die behandlung von wunden und herstellungsverfahren.
DE68923819D1 (de) Verwendung von gamma-Hydroxy-Buttersäuresalzen zur Herstellung von pharmazeutischen Zusammensetzungen zur Verwendung bei der Behandlung von Alkoholismus und die hergestellten Zusammensetzungen.
DE69421778D1 (de) Verwendung von wirksamen Mengen von aktiven Stoffen zur Behandlung von Mischhaut
DE3683333D1 (de) Mittel zur behandlung von akne vulgaris und deren herstellung.
ATE236643T1 (de) Verwendung von calendula-glykosiden zur behandlung der psoriasis
IT1164025B (it) Procedimento di produzione di una sostanza presentante un'attivita' batteriostatica
DE68924714D1 (de) Verwendung von essentiellen fettsäuren zur herstellung eines medikaments zur behandlung von ekzemen.
JPS6423842A (en) Method for allowing pulmonary respiration animal to be slaughtered to swoon
DE3671365D1 (de) Topische anwendung des 3-phenylacetylamino-2,6-piperidindions zur behandlung von hautfalten und hyperpigmentierung.
DK137589A (da) Salicylsyreholdigt middel til behandling af hudsygdomme
ATE96662T1 (de) Verwendung von c-20 bis c-26-aliphatischen alkoholen zur herstellung eines arzneimittels zur behandlung viraler infektionen.
EP0178443A3 (en) Soaps and shampoos containing bioemulsifiers
ATE136465T1 (de) Verwendung von gibberellinen zur herstellung eines arzneimittels zur behandlung von prostatitis
DE59002154D1 (de) Kombinationspraeparate enthaltend rifampicin und thioacetazon sowie gegebenenfalls isonicotinsaeurehydrazid oder ethambutol als aktive wirkstoffe.
ATE45675T1 (de) Verwendung von interferon gamma (ifn-gamma) zur herstellung von praeparationen zur behandlung rheumatischer erkrankungen.
ATE56363T1 (de) Verfahren zur herstellung von keimabgetoeteten oder in ihrer virulenz abgeschwaechten substanzen sowie deren verwendung.
ATE42201T1 (de) Verwendung von phytosterolglycosiden zur herstellung von arzneimitteln zur behandlung von erhoehtem 5(6)alpha-epoxycholesterolgehalt.
UA13475A (uk) СПОСІБ ОДЕРЖАННЯ 6-БЕНЗИЛОКСИЗАМІЩЕНИХ ІЗОПРОПІЛОВИХ ЕФІРІВ beta-КАРБОЛІН-3-КАРБОНОВОЇ КИСЛОТИ
DE69932741D1 (de) Verwendung von n-glycolneuraminsäure und deren derivaten zur herstellung eines medikaments zur behandlung von hiv-infektionen